Study of zanubrutinib plus chemo for newly diagnosed mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP or R-DHAP) helps people with untreated mantle cell lymphoma. It is for adults up to age 70 who are healthy enough for intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma and have not had treatment for it yet.
- You are between 18 and 70 years old.
- Your overall health status (ECOG score) is 0, 1, or 2.
- Your cancer is stage II, III, or IV and can be measured on scans.
- Your blood counts and organ function (kidney, liver) are within certain limits.
- You are able to take high-dose chemotherapy and have no major heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
This trial tests whether taking the targeted drug zanubrutinib continuously is better than taking it on a schedule with breaks for older adults with untreated mantle cell lymphoma. The goal is to find a treatment that works while reducing side effects.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.